Summary The aim of the paper was to determine the factors related to the initial therapy that may contribute to death from severe necrotizing acute pancreatitis and to analyze their clinical importance as well as possible additive effects. A retrospective case-control study included all adult patients treated for severe necrotizing acute pancreatitis in the Clinical Center of Kragujevac, Serbia, during the five-year period (2006-2010.). The cases (n = 41) were patients who died, while the controls (n = 69) were participants who survived. In order to estimate the relationship between potential risk factors and observed outcome, crude and adjusted odds ratios (OR) with 95 % confidence intervals (CI) were calculated in logistic regression models. Significant association with observed outcome was shown for the use of gelatin and/or hydroxyethyl starch (adjusted OR 12.555; 95 % CI 1.150-137.005), use of albumin (adjusted OR 27.973; 95 % CI 1.741-449.373), use of octreotide (adjusted OR 16.069; 95 % CI 1.072-240.821) and avoiding of enteral feeding (adjusted OR 3.933; 95 % CI 1.118-13.829), while the use of nonsteroidal anti-inflammatory drugs had protective role (adjusted OR 0.057; 95 % CI 0.004-0.805). The risk of death in patients with predicted severe necrotizing acute pancreatitis could be reduced with avoidance of treatment with colloid solutions, albumin and octreotide, as well as with an early introduction of oral/enteral nutrition and use of nonsteroidal anti-inflammatory drugs.
References
1.
TANG WF, WANG YG, ZHU L, WAN MH, CHEN GY, XIA Q, et al. Effect of somatostatin on immune inflammatory response in patients with severe acute pancreatitis. Journal of Digestive Diseases. 2007;8(2):96–102.
2.
Caraceni P, Domenicali M, Tovoli A, Napoli L, Ricci CS, Tufoni M, et al. Clinical indications for the albumin use: Still a controversial issue. European Journal of Internal Medicine. 2013;24(8):721–8.
3.
Tenner S, Baillie J, DeWitt J, Vege SS. American College of Gastroenterology Guideline: Management of Acute Pancreatitis. American Journal of Gastroenterology. 2013;108(9):1400–15.
4.
Parsi MA. NSAIDs for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography: Ready for prime time? World Journal of Gastroenterology. 2012;18(30):3936.
5.
Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple Organ Dysfunction Score. Critical Care Medicine. 1995;23(10):1638–52.
6.
Cavallini G. Somatostatin and octreotide in acute pancreatitis: the never-ending story. Digestive and Liver Disease. 2001;33(2):192–201.
7.
de-Madaria E, Soler-Sala G, Sánchez-Payá J, Lopez-Font I, Martínez J, Gómez-Escolar L, et al. Influence of Fluid Therapy on the Prognosis of Acute Pancreatitis: A Prospective Cohort Study. American Journal of Gastroenterology. 2011;106(10):1843–50.
8.
Pezzilli R, Uomo G, Gabbrielli A, Zerbi A, Frulloni L, De Rai P, et al. A prospective multicentre survey on the treatment of acute pancreatitis in Italy. Digestive and Liver Disease. 2007;39(9):838–46.
9.
Trikudanathan G, Navaneethan U, Vege SS. Current Controversies in Fluid Resuscitation in Acute Pancreatitis. Pancreas. 2012;41(6):827–34.
10.
Basurto Ona X, Rigau Comas D, Urrútia G. Opioids for acute pancreatitis pain. Cochrane Database of Systematic Reviews. 2013(7).
11.
de-Madaria E. Últimos avances en pancreatitis aguda. Gastroenterología y Hepatología. 2012;35:98–101.
12.
Gardner TB, Vege SS, Chari ST, Petersen BT, Topazian MD, Clain JE, et al. Faster Rate of Initial Fluid Resuscitation in Severe Acute Pancreatitis Diminishes In-Hospital Mortality. Pancreatology. 2009;9(6):770–6.
13.
Myburgh JA, Finfer S, Bellomo R, Billot L, Cass A, Gattas D, et al. Hydroxyethyl Starch or Saline for Fluid Resuscitation in Intensive Care. New England Journal of Medicine. 2012;367(20):1901–11.
14.
Marshall JC. The Multiple Organ Dysfunction (MOD) Score. Sepsis. 1997;1(1):49–52.
15.
Aufenanger J, Samman M, Quintel M, Fassbender K, Zimmer W, Bertsch T. Pancreatic Phospholipase A2 Activity in Acute Pancreatitis: a Prognostic Marker for Early Identification of Patients at Risk. Clinical Chemistry and Laboratory Medicine. 2002;40(3).
16.
Wang G, Wen J, Wen P, Wilbur RR, Zhou SF, Xiao X. The Effect of Somatostatin, Ulinastatin and Salvia miltiorrhiza on Severe Acute Pancreatitis Treatment. The American Journal of the Medical Sciences. 2013;346(5):371–6.
17.
Andersson B, Appelgren B, Sjödin V, Ansari D, Nilsson J, Persson U, et al. Acute pancreatitis – costs for healthcare and loss of production. Scandinavian Journal of Gastroenterology. 2013;48(12):1459–65.
18.
Wall I, Badalov N, Baradarian R, Iswara K, Li JJ, Tenner S. Decreased Mortality in Acute Pancreatitis Related to Early Aggressive Hydration. Pancreas. 2011;40(4):547–50.
19.
Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, et al. Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013;62(1):102–11.
20.
Mäkelä A, Kuusi T, Schröder T. Inhibition of serum phospholipase-A2in acute pancreatitis by pharmacological agentsin vitro. Scandinavian Journal of Clinical and Laboratory Investigation. 1997;57(5):401–7.
21.
Zhao G. Effects of different resuscitation fluid on severe acute pancreatitis. World Journal of Gastroenterology. 2013;19(13):2044.
22.
Wang G, Wen J, Xu L, Zhou S, Gong M, Wen P, et al. Effect of enteral nutrition and ecoimmunonutrition on bacterial translocation and cytokine production in patients with severe acute pancreatitis. Journal of Surgical Research. 2013;183(2):592–7.
23.
Johnson CD. Persistent organ failure during the first week as a marker of fatal outcome in acute pancreatitis. Gut. 2004;53(9):1340–4.
24.
Uhl W, Buchler MW, Malfertheiner P, Beger HG, Adler G, Gaus W, et al. A randomised, double blind, multicentre trial of octreotide in moderate to severe acute pancreatitis. Gut. 1999;45(1):97–104.
25.
Krinsley JS. Association Between Hyperglycemia and Increased Hospital Mortality in a Heterogeneous Population of Critically Ill Patients. Mayo Clinic Proceedings. 2003;78(12):1471–8.
26.
Doctor N, Agarwal P, Gandhi V. Management of Severe Acute Pancreatitis. Indian Journal of Surgery. 2012;74(1):40–6.
27.
Chan YC, Leung PS. Acute Pancreatitis. Pancreas. 2007;34(1):1–14.
28.
Marik PE, Raghavan M. Stress-hyperglycemia, insulin and immunomodulation in sepsis. Intensive Care Medicine. 2004;30(5):748–56.
29.
Nevalainen TJ. The role of phospholipase A2 in human acute pancreatitis. Klinische Wochenschrift. 1989;67(3):180–2.
30.
Petrov MS, Zagainov VE. Influence of enteral versus parenteral nutrition on blood glucose control in acute pancreatitis: A systematic review. Clinical Nutrition. 2007;26(5):514–23.
31.
Schütte K, Malfertheiner P. Markers for predicting severity and progression of acute pancreatitis. Best Practice & Research Clinical Gastroenterology. 2008;22(1):75–90.
32.
Sotoudehmanesh R, Khatibian M, Kolahdoozan S, Ainechi S, Malboosbaf R, Nouraie M. Indomethacin May Reduce the Incidence and Severity of Acute Pancreatitis After ERCP. The American Journal of Gastroenterology. 2007;102(5):978–83.
33.
Petrov MS, Shanbhag S, Chakraborty M, Phillips ARJ, Windsor JA. Organ Failure and Infection of Pancreatic Necrosis as Determinants of Mortality in Patients With Acute Pancreatitis. Gastroenterology. 2010;139(3):813–20.
34.
Khoshbaten M, Khorram H, Madad L, Ehsani Ardakani MJ, Farzin H, Zali MR. Role of diclofenac in reducing post‐endoscopic retrograde cholangiopancreatography pancreatitis. Journal of Gastroenterology and Hepatology. 2008;23(7pt2).
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
